# Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)

> **NCT03180619** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 124 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** TAF

## Key facts

- **NCT ID:** NCT03180619
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-29
- **Primary completion:** 2019-03-27
- **Final completion:** 2020-09-04
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2021-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03180619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03180619, "Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03180619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*